Compare Simon Property Group Inc (SPG) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Simon Property Group Inc vs 10X Genomics Inc — how do they compare? Simon Property Group Inc trades at $206.11 (market cap $68.56B), while 10X Genomics Inc trades at $67.59 (market cap $8.55B). The key difference: Simon Property Group Inc is far larger — about 8× 10X Genomics Inc's market cap, and Simon Property Group Inc pays a 4.2% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| SPG | TXG | |
|---|---|---|
Market Cap | $68.56B | $8.55B |
Sector | Real Estate | Health |
52-Week High | $236.70 | $67.29 |
52-Week Low | $173.35 | $11.34 |
Enterprise Value | $97.00B | $8.08B |
Dividend Yield | 4.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPG trades at $211.88, up 1.17% daily, with a bearish technical signal but strong fundamentals including a P/E of 14.95, robust net income margin of 66.57%, and recent Q2 2026 FFO beat. The company raised $800 million in senior notes (PRNewsWire, 2026-09-09) and launched Simon Media Network to monetize mall traffic (PRNewsWire, 2026-08-27), enhancing growth prospects despite a Q2 EPS miss.
Outlook is mixed: analyst consensus targets $231.82 with 42% buy ratings, but risks include high debt ($24.21B long-term) and bearish technicals. Opportunities lie in dividend yields and media initiatives, while headwinds involve retail real estate volatility and interest rate sensitivity.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
